FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145364162> ?p ?o ?g. }

• W2145364162 endingPage "120" @default.
• W2145364162 startingPage "106" @default.
• W2145364162 abstract "Ligand-receptor mediated targeting may affect differently the performance of supramolecular drug carriers depending on the nature of the nanocarrier. In this study, we compare the selectivity, safety and activity of doxorubicin (Dox) entrapped in liposomes versus Dox conjugated to polymeric nanocarriers in the presence or absence of a folic acid (FA)-targeting ligand to cancer cells that overexpress the folate receptor (FR). Two pullulan (Pull)-based conjugates of Dox were synthesized, (FA-PEG)-Pull-(Cyst-Dox) and (NH2-PEG)-Pull-(Cyst-Dox). The other delivery systems are Dox loaded PEGylated liposomes (PLD, Doxil®) and the FR-targeted version (PLD-FA) obtained by ligand post-insertion into the commercial formulation. Both receptor-targeted drug delivery systems (DDS) were shown to interact in vitro specifically with cells via the folate ligand. Treatment of FR-overexpressing human cervical carcinoma KB tumor-bearing mice with three-weekly injections resulted in slightly enhanced anticancer activity of PLD-FA compared to PLD and no activity for both pullulan-based conjugates. When the DDS were administered intravenously every other day, the folated-Pull conjugate and the non-folated-Pull conjugate displayed similar and low antitumor activity as free Dox. At this dosing regimen, the liposome-based formulations displayed enhanced antitumor activity with an advantage to the non-folated liposome. However, both liposomal formulations suffered from toxicity that was reversible following treatment discontinuation. Using a daily dosing schedule, with higher cumulative dose, the folated-Pull conjugate strongly inhibited tumor growth while free Dox was toxic at this regimen. For polymeric constructs, increasing dose intensity and cumulative dose strongly affects the therapeutic index and reveals a major therapeutic advantage for the FR-targeted formulation. All DDS were able to abrogate doxorubicin-induced cardiotoxicity. This study constitutes the first side-by-side comparison of two receptor-targeted ligand-bearing systems, polymer therapeutics versus nanoparticulate systems, evaluated in the same mouse tumor model at several dosing regimens." @default.
• W2145364162 created "2016-06-24" @default.
• W2145364162 creator A5004129931 @default.
• W2145364162 creator A5016187996 @default.
• W2145364162 creator A5017114776 @default.
• W2145364162 creator A5018210928 @default.
• W2145364162 creator A5037456471 @default.
• W2145364162 creator A5047123448 @default.
• W2145364162 creator A5050764524 @default.
• W2145364162 creator A5056988151 @default.
• W2145364162 creator A5060158935 @default.
• W2145364162 creator A5061202040 @default.
• W2145364162 creator A5070679444 @default.
• W2145364162 creator A5075879267 @default.
• W2145364162 date "2015-06-01" @default.
• W2145364162 modified "2023-09-27" @default.
• W2145364162 title "A comparative study of folate receptor-targeted doxorubicin delivery systems: Dosing regimens and therapeutic index" @default.
• W2145364162 cites W1278072151 @default.
• W2145364162 cites W146281208 @default.
• W2145364162 cites W148530083 @default.
• W2145364162 cites W18052831 @default.
• W2145364162 cites W1936102867 @default.
• W2145364162 cites W1963718873 @default.
• W2145364162 cites W1965063429 @default.
• W2145364162 cites W1970829695 @default.
• W2145364162 cites W1975762038 @default.
• W2145364162 cites W1976356368 @default.
• W2145364162 cites W1976748056 @default.
• W2145364162 cites W1979125559 @default.
• W2145364162 cites W1982426647 @default.
• W2145364162 cites W1986269836 @default.
• W2145364162 cites W1986714589 @default.
• W2145364162 cites W1989353157 @default.
• W2145364162 cites W1993147241 @default.
• W2145364162 cites W1993562925 @default.
• W2145364162 cites W1994451429 @default.
• W2145364162 cites W2004529378 @default.
• W2145364162 cites W2005572726 @default.
• W2145364162 cites W2011886457 @default.
• W2145364162 cites W2017052005 @default.
• W2145364162 cites W2018478612 @default.
• W2145364162 cites W2019042150 @default.
• W2145364162 cites W2020876383 @default.
• W2145364162 cites W2021661404 @default.
• W2145364162 cites W2023298707 @default.
• W2145364162 cites W2024787650 @default.
• W2145364162 cites W2029118887 @default.
• W2145364162 cites W2030855909 @default.
• W2145364162 cites W2033263935 @default.
• W2145364162 cites W2037009133 @default.
• W2145364162 cites W2045920893 @default.
• W2145364162 cites W2050146398 @default.
• W2145364162 cites W2051027441 @default.
• W2145364162 cites W2051165400 @default.
• W2145364162 cites W2052392928 @default.
• W2145364162 cites W2056644518 @default.
• W2145364162 cites W2058296189 @default.
• W2145364162 cites W2059965787 @default.
• W2145364162 cites W2066292216 @default.
• W2145364162 cites W2067121848 @default.
• W2145364162 cites W2067358289 @default.
• W2145364162 cites W2070431417 @default.
• W2145364162 cites W2071334987 @default.
• W2145364162 cites W2072554913 @default.
• W2145364162 cites W2080234659 @default.
• W2145364162 cites W2080464257 @default.
• W2145364162 cites W2084329943 @default.
• W2145364162 cites W2087842405 @default.
• W2145364162 cites W2098268167 @default.
• W2145364162 cites W2111901647 @default.
• W2145364162 cites W2118878458 @default.
• W2145364162 cites W2120331308 @default.
• W2145364162 cites W2125359528 @default.
• W2145364162 cites W2126044151 @default.
• W2145364162 cites W2127168225 @default.
• W2145364162 cites W2128389838 @default.
• W2145364162 cites W2134358966 @default.
• W2145364162 cites W2144346703 @default.
• W2145364162 cites W2148649439 @default.
• W2145364162 cites W2148845753 @default.
• W2145364162 cites W2153091833 @default.
• W2145364162 cites W2155035501 @default.
• W2145364162 cites W2157023900 @default.
• W2145364162 cites W2162259135 @default.
• W2145364162 cites W2162495360 @default.
• W2145364162 cites W2320882980 @default.
• W2145364162 cites W2331088080 @default.
• W2145364162 doi "https://doi.org/10.1016/j.jconrel.2015.04.009" @default.
• W2145364162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25869964" @default.
• W2145364162 hasPublicationYear "2015" @default.
• W2145364162 type Work @default.
• W2145364162 sameAs 2145364162 @default.
• W2145364162 citedByCount "62" @default.
• W2145364162 countsByYear W21453641622015 @default.
• W2145364162 countsByYear W21453641622016 @default.
• W2145364162 countsByYear W21453641622017 @default.
• W2145364162 countsByYear W21453641622018 @default.
• W2145364162 countsByYear W21453641622019 @default.

• next